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ABSTRACT: The success of the global tuberculosis (TB) control program has been threatened with drug 
resistant strains emergence; especially the Multidrug Resistant Tuberculosis (MDR-TB). Despite that Nigeria 
is one of the countries with high tuberculosis burden, little is known on the magnitude of MDR-TB in the 
country. This study was to determine drug resistant patterns of Mycobacterium tuberculosis isolated from 
patients that attended Directly Observed Treatment Short-course (DOTS) centres in Ibadan, Nigeria. Sputum 
samples collected from confirmed TB patients were processed using the N-acetyl L-cysteine-sodium 
hydroxide decontamination method. Direct drug susceptibility test was carried out against rifampicin, 
isoniazid, ethambuthol and streptomycin. Out of the 319 samples collected, 149 (46.7%) were culture positive 
and susceptibility test was completed for 101 (67.8%) isolates, out of which any resistance and mono-
resistance to rifampicin was 23.8% and 8.9% respectively. In all 11.9% MDR-TB was observed comprising 
30.8% (acquired), and 8.3% (primary) while, 3.96% showed resistance to all tested drugs. The patterns of 
MDR-TB in this study indicates that active case findings as well as expansion of drug susceptibility testing is 
required to effectively control TB, drug resistant strains and to forestall the transmission and spread of the 
drug-resistant TB in the society.  
Keywords: Tuberculosis; Multi-drug resistant tuberculosis; Directly observed treatment short-course; 
Antibiotics resistance. 
1. INTRODUCTION 
Tuberculosis (TB), a chronic infectious disease is responsible for majority of ill health all over the 
world. The disease can affect anyone; however, about 90% of those that develops the disease are adults while 
the male: female ratio is 2:1 [1]. Globally, TB is one of the leading causes of death, and highest number of 
causalities from a single infectious agent especially among people living with Human Immunodeficiency 
Virus (HIV) infection [2, 3]. Despite efforts to control TB epidemic, the estimated incident cases of TB in 
2017 was 10 million in 133 per 100, 000 population and 1.57 million deaths which represented 1.8% and 
3.9% declines from the 2016 incident cases respectively [4]. While, in 2018, 10 million fell ill with TB, 1.2 
million (1.1-1.3 million) among HIV-negative people and 251000 among HIV infected individuals died of TB 
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[1]. The emergence of drug-resistant strains of Mycobacterium tuberculosis, especially the multidrug resistant 
TB (MDR-TB), extensively drug resistant TB (XDR-TB) and lately the total drug resistant TB (TDR-TB) is a 
threat to the control of TB program worldwide [5]. The report of drug resistant in TB was as soon as first TB 
drugs were made available for therapy in the late 1940’s [6]. It was believed that there could be a reduction in 
the trend with quality-assured multidrug treatment; hence the introduction and implementation of the DOTS 
program in the early 1990’s [7]. The global implementation of the strategy led to the cure of about 50 million 
patients, and prevention of about 7 million deaths in comparison with the pre-DOTS era. However, the 
strategy has been unable to stop the alarming increase of the resistant strains of TB [8, 9]. Patients infected 
with MDR strains are those that are resistant to rifampicin and isoniazid (the powerful anti-TB medications) 
with or without resistant to other drugs. This kind of infection complicates the length of treatment because 
they do not respond to the WHO DOTS therapy and require treating patients with second line drugs that are 
more toxic, more expensive, and less effective with longer time of treatment [3].  
In Nigeria, TB remains a major infectious disease and for long years, the country has remained one 
of the highest TB burdened countries of the world. Currently, among the 30 high TB burden countries of the 
world, Nigeria is ranked 7th, while the country is ranked 2nd in Africa behind South Africa with a total of 429 
(280-609) cases per 1000.000 populations in 2018 [1, 3]. Incidentally, Nigeria is not even among the eleven 
High Burden Countries (HBC) that were reported to be on track to reach the 2020 milestone of a 20% in the 
reduction rate of TB incidence [1]. The report of the WHO showed that Nigeria is among the high TB/HIV 
and MDR/RR-TB burden countries of the world. In 2017, the overall estimated rate of MDR/RR-TB in the 
country was 4.3% and 15% among new and previously treated cases respectively [3]. While in 2018, 4.3% 
(3.2-5.5) was the TB estimated proportion with MDR/RR-TB among the new and 15% (11-19) among the 
previously treated cases [1]. Although, it has been suggested that surveillance study should be continuous with 
regular drug resistance determination. The surveillance should be based on routine drug susceptibility testing 
especially, in countries with high burden the disease. Through these, the level and trends of antimicrobial 
resistance will be accessed [1]. However, reports of study on the determination of the prevalence of MDR-TB 
in Nigeria including Ibadan where the disease is on the rise are limited. Some of the few studies in Nigeria 
include the 16% and 11.7% reported in Jos and Calabar, respectively [10, 11]. In addition, 53% prevalence 
was reported in Ibadan in a study carried out at the University Teaching Hospital (UCH), a referral hospital 
[12]. While it was noted in the study that the report cannot be used to ascertain MDR-TB magnitude in the 
city, it has also been previously pointed out that reported figures from studies carried out at tertiary care 
hospitals and referral centres are usually high and may not represent the true state of the general population 
[13]. This study was therefore designed with the aim of determining the drug resistance in Mycobacterium 
tuberculosis isolated from TB patients that attended the DOTS centres in Ibadan, Nigeria. 
2. MATERIALS AND METHODS 
2.1. Study Area 
The study was a cross sectional study and samples were collected from 11 DOTS in Ibadan, Nigeria 
between January 2010 and November 2011. The centres included: Chest Hospital, Jericho; TBL Health 
Centre, Moniya; TBL Health Centre, Iwo- Road; Oluyole TBL Health Centre Ibadan;  Molete TBL clinic; 
Egbeda TBL Health Centre; Adeoyo Teaching hospital Maternity, Yemetu; Adifase TBL centre Apata; Alafara 
TBL centre; Atolu TBL centre Oremeji and Ido TBL centre Ido (Figure 1). Ibadan lies between Latitude 
7o32’N and Longitude 3o54’E. 
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Figure 1. Map of Ibadan region showing the DOTS centers where samples were collected. 
 
2.2. Study participants 
The study participants included the consecutive patients seen at the DOTS clinics that were 
diagnosed for pulmonary TB either by ZN staining and/or X-ray with the help of the health officials. 
2.3. Ethical consent and ethical approval 
Consents were sought from adult participants who volunteered to participate in the study after 
adequate information on study objectives and implications were given. Consents were sought from 
parents/guardians of children included in the study. The study was approved by the University of 
Ibadan/University College Hospital Ethical committee (Approval number: NHREC/05/01/2008a). 
2.4. Inclusion and exclussion criteria 
Confirmed TB patients at the DOTS centres who gave consent and  had not commenced anti-TB 
therapy were included. Those already on anti-TB treatment, those who declined to participate in the study and 
those that could not expectorate were excluded.  
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2.5. Sputum sample collection and processing 
The samples were collected in leak-proof and clean sputum containers. With the help of the health 
officials, clear instructions were given to patients on how to produce the samples. Where feasible, three 
specimens were collected; on-the-spot, early morning, on-the-spot. The samples were properly labelled and 
transported in iced pack to the laboratory on the day of  collection. The samples were stored in a refrigerator 
and processed within 48 hours of collection. Processing of the sputum samples were done using the BD 
BBLTM MycoprepTM N-Acetyl L-Cysteine-sodium hydroxide (NALC-NaOH) decontamination method [14].  
2.6. Quality control 
Reference strains of fully susceptible H37RV (ATCC 27294), and MDR (ATCC 35838) M. 
tuberculosis obtained from the Division of Infectious Diseases, North-western University, Feinberg School of 
Medicine, Chicago, USA was used as control. These strains were sub-cultured freshly on Lowenstein Jensen 
(L-J) medium before use. For every batch of culture, the reference strains were inoculated and incubated 
alongside all test samples. 
2.7. Direct drug susceptibility testing 
This was done using L-J medium in accordance with the laboratory’s standard procedure previously 
described [15, 16]. The critical concentration used for each drug was as recommended [16, 17]. Critical 
concentrations of 0.2 µg/ml (isoniazid) 40 µg/ml (rifampicin), 4.0 µg/ml (streptomycin) and 2.0 µg/ml 
(ethambuthol) were used. Preparation of the  L-J medium with or without antimicrobials and inoculation of 
the media as well as interpretation of susceptibility test results was as previously descibed [18]. The tubes 
were incubated at 37°C. Final susceptibility results was reported after 40 days following the laboratory’s 
standard procedure, but preliminary results were reported earlier for resistant strains (the earliest observation 
day was 14 days).   
2.8. Definition of MDR-TB and Poly-drug resistance 
The MDR-TB was defined according to the definition of W.H.O. (i.e resistance to rifampicin and 
isonoazid with or witout resistance to any other drugs). While poly-drug resistance was defined as resistance 
to more than one drug but not including both rifampicin and isoniazd at the same time.   
2.9. Data analysis 
The antibiotics resistance prevalence of the isolates was calculated and expressed in percentages. The 
association between the primary and acquired drug resistance was analysed using descripitive statistics and 
ANOVA at p=0.05 
3. RESULTS  
Out of the 319 samples collected, 149 (46.7%) were culture positive and drug susceptibility results 
was completed for 101 (67.8%), comprsising 60 (59.4%) new, 13 (12.9%) retreatment and 28 (27.7%) 
unclassified cases. Mycobacterium tuberculosis prevalence in relation to patient’s age is shown in Table 1. 
The highest prevalent rate (47.5%) was between the age range 15-34 years followed by the age range 35-54. 
The least rate (0.99%) was within the age range of less than 15 years. Among the 74 (73.3%) patients with 
known HIV status, 51 (85.0%), 10 (76.9%), and 13 (46.4%)  were new, retretament and unclassified cases, 
respectively (Table 1). The drug susceptibility patterns of the isolates showed that 22 (36.6%) out of the 60 
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new cases were susceptible to all the four drugs while, out of the 13 isolates from the retreatmet cases, 6 
(46.2%) were susceptible to the four drugs, but 12 (42.9) were susceptible to the four drugs among the 28 
isolates obtained from the unclassified cases (Table 2). Furthermore, any resistance to rifampicin was 14 
(23.3%) among the new and 5 (38.5%) among the retreatment cases. Any resistance to ethambuthol was 9 
(15.0%) and 3 (23.1%) among the new and the retreatment cases, respectively (Table 2).  
 
Table 1. Baseline characteristics of case-patients in a study of MDR TB, Ibadan, Nigeria. 
Characteristics New (%), n=60 Retreatment (%), n=13 Unclassified (%), n=28 Total (%), n=101 
Age, y     
< 15 1 (1.7) 0 0 1 (0.99) 
15-34 29 (48.3) 8 (61.5) 11 (39.3) 48 (47.5) 
35-54 24 (40.0) 3 (23.1) 13 (46.4) 40 (39.6) 
≥ 55 6 (10.0) 2 (15.4) 4 (14.3) 12 (11.9) 
Sex 
Male 31 (51.7) 6 (46.1) 11 (39.3) 4 (47.5) 
Female 29 (48.3) 7 (53.8) 17 (60.7) 53 (52.5) 
Recruitment centres 
Ade Oyo 2 (3.3) 3 (23.1) 11 (39.3) 
16 
(15.8) 
Adifase 9 (15.0) 5 (38.5) 2 (7.1  16 (15.8) 
Alafara 7 (11.7) 1 (7.7) 2 (7.1) 10 (9.9) 
Atolu 0 0 2 (7.1) 2 (1.98) 
Egbeda 1 (1.7) 0 0 1 (0.99) 
Ido 0 0 4 (14.3) 4 (3.96) 
Iwo Road 3 (5.0) 0 0 3 (2.97) 
Jericho 19 (31.7) 3 (23.1) 5 (17.9) 27 (26.7) 
Molete 11 (18.3) 0 0 11(10.9) 
Olomi 0 1 (7.1) 1 (3.6) 2 (1.98) 
UCH 8 (13.3) 0 1 (3.6) 9 (8.9) 
HIV status known 
 51 (85.0) 10 (76.9) 13 (46.4) 74 (73.3) 
 
Among the unclassified cases, any resistance to isoniazid was 19 (35.7%) while it was 4 (14.3%) for 
both streptomycin and ethambuthol. Monoresistance to rifampicin was highest (11.7%) among the new cases, 
while it was 5.0% to ethambuthol. Among the unclassified cases, the highest monoresistance was to 
ethambuthol, but the lowest was to streptomycin. In all, 12 (11.9%) were MDR-TB out of which 5 (8.3%) 
were from the new cases, 4 (30.8%) from retreatment cases and 3 (10.7%) from unclassified cases. The other 
drug resistance aside MDR-TB showed that 3 (5.0%) isolates among those from new cases showed resistance 
to both isoniazid and ethambuthol while, two (2) isolates each from the new cases were resistant to a 
combination of isoniazid and streptomycin and a combination of rifampicin and streptomycin respectively. 
Among the retreatment cases, only one isolate was resistant to a combination of rifampicin and streptomycin 
while, among the uncassified cases, three (10.7%) were resistant to three drugs (isoniazid, streptomycin and 
ethambuthol). Furthermore, while 4 (3.96) isolates were pan resistant (resistance to all the four drugs), 8.3%, 
30.8% and 10.7% of the MDR-TB were primary, acquired and unclassified respectively. Moreover, 7 (58.3%) 
and 5 (41.7%) MDR-TB were from females and male patients respectively (Table 2). However, there was no 
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statistical significant difference in the pattern of resistance between the new and the retreatment cases                
(p = 0.87). 
 
Table 2. Drug resistance pattern of the isolates to first line drug in new and previously treated cases.  
 New, n=60 Retreatment, n=13 Unclassified, n=28 Total, n=101 
 No (%) No (%) No (%) No (%) 
Resistance patterns 
Susceptible to all first line drugs 22 (36.6) 6 (46.2) 12 (42.9) 40 (39.6) 
Any resistance 
RIF 14 (23.3) 5 (38.5) 5 (17.9) 24 (23.8) 
INH 13 (21.7) 4 (30.8) 10 (35.7) 27 (26.7) 
SM 12 (20.0) 3 (23.1) 4 (14.3) 19 (18.8) 
EMB 9 (15.0) 3 (23.1) 4 (14.3) 16 (15.8) 
Mono resistance 
RIF 7 (11.7) 0 2 (7.1) 9 (8.9) 
INH 3 (5.0) 0 4 (14.3) 7 (6.9) 
SM 5 (8.3) 0 1 (3.6) 6 (5.9) 
EMB 3 (5.0) 1 (7.7) 3 (10.7) 7 (6.9) 
MDR 
RIF + INH 2 (3.3) 2 (15.4) 2 (7.1) 6 (5.9) 
RIF +INH +EMB 1 (1.7) 0 0 1 (0.99) 
RIF +INH +SM 1 (1.7) 0 0 1 (0.99) 
RIF +INH +SM +EMB 1 (1.7) 2 (15.4) 1 (3.6) 4 (3.96) 
Total MDR 5 (8.3) 4 (30.8) 3 (10.7) 12 (11.9) 
Prevalence of MDR by sex 
Male 4 (33.3) 0 1 (8.3)  
Female 3 (25.0) 2 (16.7) 2 (7.1)  
Resistance patterns to other first line drugs aside MDR 
INH + SM 2 (3.3) 0 0 2 (1.98) 
SM +EMB 1 (1.7) 0 0 1 (0.99) 
RIF +SM 2 (3.3) 1 (7.7) 0 3 (2.98) 
INH +EMB 3 (5.0) 0 0 3 (2.98) 
INH +SM +EMB 0 0 3 (10.7) 3 (2.98) 
 
4. DISCUSSION  
The pattern of drug resistance of TB isolates from patients in DOTS centres in Ibadan, Nigeria was 
examined in the present study. The 59.4%, 12.9% and 27.8% patients that were new, retreatment, and 
unclassified TB cases differs from the report of a similar study in the northern part of the country where 
37.2%, 40.7% and 22.1% new, re-treatment and unclassified cases respectively were reported [10]. The 
observed resistance to anti-TB drugs in this study is high with 60.4% resistant to at least one drug compared 
to the 35.7% and 15.3% reported in India and the 48.6% from Kenya [20-22]. These countries are also among 
the 30 TB high burdened countries like Nigeria. The observation was also higher than the 7.8% reported in 
USA [22], but is comparably similar to the 68.1% of resistance to at least one drug reported in Lima,                   
Peru [23].   
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Of the 60.4% resistant to at least one drug in this study, 6.6% were ‘pan resistant’ which is lower 
compared to 11.4% previously reported [23]. Furthermore, the 39.6% that were observed to be fully 
susceptible in this study is lower compared to the reported 76.0% in Northern Nigeria [11], 76.5% in Ghana, a 
neighbouring West African country [24], 73.8% in Kenya [21] and 92.2% in USA [22]. The mono-resistance, 
8.9% (RIF), 6.9% (INH), 5.0% (SM) and 4.0% (EMB) observed in this study is lower compared to 3.0% 
(RIF), 0% (INH), 11.0% (SM) and 1.0% (EMB) reported in Jos except for SM [10]. The observation is also 
similar to the report of previous studies in Ghana and USA where lower mono-resistance was also reported 
[22, 24]. Furthermore, the mono-resistant observed in this study is lower compared to the 5.3% (INH), 4.3% 
(RIF), 0.3% (EMB) and 4.3% (SM) as well as 6.3% (INH) and 0.2% (RIF) reported from studies in Italy and 
USA respectively [22, 25]. The reason for the disparity may be because drug-resistant TB is not a major 
health problem in countries with good national TB control programs like Western Europe, except for the 
increasing immigrants [25, 26].  In addition, the mono-resistance of the isolates in this study among the new 
patients and the previously treated cases are not in agreement with the report from a similar study in Kenya. 
Isoniazid (6.9%) and rifampicin (8.9%) mono-resistance in this study also differs from the 16% (isoniazid) 
and 0% (rifampicin) reported in Russia [27].  
Any resistance of the isolates to the four drugs in this study that were 23.3%, 21.7%, 20.0% and 
15.0% among the new cases were higher than the 8.0%, 13.4%, 8.2% and 13.4% respectively to RIF, INH, 
SM and EMB in another study conducted in Swaziland [28]. Also, while the mono-resistant of the isolates 
from the new cases in this study was 11.7% (RIF), 5.0% (INH), 8.3% (SM) and 5.0% (EMB), it was 0.3% 
(RIF), 1.4% (INH), 1.7% (SM) and 0% (EMB) in the latter study. The reason for this disparity may be due to 
the burden of TB in both countries. While Nigeria has for a long time remained among the high burden 
countries, Swaziland is not. Moreover, any resistance to RIF (23.8%), INH (26.7%), SM (18.8%) and EMB 
(15.8%) observed in this study is lower compared to 78.1% (RIF), 92.7% (INH), 61.0% (SM) and 91.5% 
(EMB) reported from another study in the southern part of the country [29]. This might be due to the fact that 
the TB control program in the location of the present study is better compared to that of the latter study. The 
11.9% MDR-TB in this study is comparably similar to 12.0%, 13.7% and 10.6% reported from similar studies 
in Pune (India), Cotonou (Republic of Benin) and China, respectively [19, 30, 31]. The observation is 
however higher than the reported 2.0% in Ghana [24], 6.6% in Cameroun [32], 4.8% in Kenya [21], 5.7% and 
5% in India [20, 33], 4.0% in Mongolia [34], 1.2% in USA, 8.9% in Somalia [35] and 1.1% in Italy [25]. 
However, the observed MDR-TB in this study is lower compared to the 24.0% reported among high risk 
groups in Zimbabwe, another African country [36]. 
In Nigeria, previous MDR-TB reported from similar studies was a bit higher, though comparable to 
the findings of the present study. In Jos (Northern Nigeria) and Abeokuta (Southwestern Nigeria), 16% and 
17.6% prevalence were reported respectively [1, 37]. However, the MDR-TB (11.9%) observed in this study, 
is higher than the 5.8% reported from a study carried out in three hospitals in Abeokuta [38]. Furthermore, the 
observation is far lower compared to the 53.0% previously reported from another study in the same city [12]; 
the reason for the disparity might be due to the study centers. While the latter study was in a referral hospital 
that receives patients with chronic medical conditions from different parts of the country; the participants for 
the present study were drawn from the DOTS centers most of which are in primary health care centres. There 
could therefore have been selection bias in the latter study and some cases that might have previously failed 
TB treatment may be regarded as new cases [10]. This is coupled with the fact that figures of tertiary care 
hospitals and referral centers are usually high compared to what is obtainable among the general population 
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[13]. The total drug resistance observed in this study was also high especially for RIF (23.3%), regarded as a 
surrogate marker for MDR-TB alongside that of INH (21.7%).  
The primary MDR-TB (8.3%) observed in this study was lower than the acquired MDR-TB (30.8%) 
which is also in agreement with the report of another study in Jaipur with 4.5% primary and 24.3% acquired 
MDR-TB (24.3%). Also in Somalia, 5.2% and 40.8% primary and acquired MDR-TB respectively was 
reported [36, 30]. However, the acquired resistance in the present study is a bit lower compared to 38.6% and 
43.8% previously reported from other studies in Russia and China respectively [27, 31]. But, the current 
observation is not in agreement with the 51.7% and 34.9% primary and acquired MDR-TB, respectively 
reported in Thailand, another HBC [40]. Similarly, the primary and acquired MDR-TB in this study is not in 
line with a lower prevalence of 1.7% and 12.0% respectively, reported in India [20]; as well as the 2% 
(primary) and 29.4% (acquired) reported in Kenya [21]. Moreover, this observation is also higher than the 4% 
(primary) and 18% (acquired) from Jos, a city in the Northern part of Nigeria [10]. That there was no 
statistical significance difference (p = 0.87) in the MDR-TB cases among HIV-negative and HIV-positive 
patients in this study agrees with previous reports in Argentina and USA [22, 41]. 
The patterns of MDR in this study, RIF-INH (5.9%), RIF-INH-EMB (0.99%), RIF-INH-SM (0.99%) 
and RIF-INH-SM-EMB (3.96%) is not in agreement with the RIF-INH (4.9%), RIF-INH-EMB (1.2%), RIF-
INH-SM (23.2%) and RIF-INH-SM-EMB (42.7%) previously reported [29]. Consequently, the observed 
poly-drug resistance (INH-SM, 8.5%; INH-SM-EMB, 11.0%) reported in another study [29] was higher than 
the patterns (INH-SM, 1.8%; INH-SM-EMB, 2.98%) in this study. The reason for the disparity may be as a 
result of geographical locations of the study sites and more importantly as a result of better control program in 
our study area which enjoy supports from a Belgian non-Governmental organization (Daimen Foundation). 
Nonetheless, this study has some limitations; first, the sample size was small. Second, patients already on 
anti-TB treatment at the time of recruitment were excluded; hence some MDR cases could have been screened 
out. Third, it was only the population of those that presented at the health care centres that were included and 
transport costs could have limited access to care of some other patients.  
In conclusion, a high MDR-TB prevalence was observed in the study. It is however not as alarming 
as was previously reported over a decade ago. The study also showed that primary MDR-TB is common in 
the overall burden of the MDR-TB in the city. Hence, active case findings in addition to expanding the drug 
susceptibility testing especially for the new TB patients is highly required to effectively control TB and drug 
resistant strains and to forestall the transmission and spread of the drug-resistant TB in the society.    
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